MedImmune,the biotech division of pharma titan AstraZeneca,has been selected as a strategic research partner by Inserm,the French National Institute of Health and Medical Research.The three-year collaboration seeks to advance research in oncology,respiratory,inflammatory and autoimmune diseases.
The research aims to move discoveries from bench to bedside,helping patients with unmet medical needs through exploring disease mechanisms and potential candidate drugs.
Also involved in the research is the private subsidiary of Inserm,Inserm Transfert.Inserm Transfert manages research projects,supporting studies from the preclincal to the postmarketing,and providing seed financing for biotech projects.
Inserm has 10 strategic research partners and 500 collaborators in total.It is closely associated with university hospital personnel and foreign research scientists.
Inserm's CEO,Professor Andre Syrota,said they are confident they will benefit from MedImmune's strong support of their efforts to foster discovery of new targets in therapy areas with high unmet medical needs.
MedImmune is based in Gaithersburg,Maryland.It is perhaps best known for its FluMist vaccine product.
AstraZeneca(AZN)
No comments:
Post a Comment